Key result
Intravenous ferric carboxymaltose is safe and effective for iron repletion in symptomatic patients with heart failure with reduced ejection fraction, whereas oral iron supplementation is not effective.
Why the study?
Does iron therapy improve outcomes in patients with heart failure and iron deficiency?
Population
Patients with heart failure and iron deficiency
Design
Review
Authors
Loading...
Supports IV iron repletion in symptomatic HFrEF with iron deficiency; leaves open effects on hard clinical outcomes.
Does iron therapy improve outcomes in patients with heart failure and iron deficiency?
Intravenous iron supplementation, specifically ferric carboxymaltose, is recommended for symptomatic patients with heart failure with reduced ejection fraction and iron deficiency, while oral iron is ineffective.
Drozd et al. (2016) conducted a review in Heart failure and iron deficiency. Intravenous iron therapy (ferric carboxymaltose) vs. Oral iron or placebo was evaluated. Intravenous ferric carboxymaltose is safe and effective for iron repletion in symptomatic patients with heart failure with reduced ejection fraction, whereas oral iron supplementation is not effective.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: